Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate whether chronic dosing with Niaspan™ increases reverse cholesterol
transport, high-density lipoprotein cholesterol (HDL-C) levels, and fecal excretion of
cholesterol.